GCM
SAGE icon

Graham Capital Management’s Sage Therapeutics SAGE Stock Holding History

Graham Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-154,051
Closed -$1.4M – 1598
2025
Q2 		$1.4M Buy
154,051
+61,808
+67% +$455K 0.02% 472
2025
Q1 		$733K Buy
92,243
+17,276
+23% +$126K 0.01% 653
2024
Q4 		$407K Sell
74,967
-11,651
-13% -$71.2K 0.01% 816
2024
Q3 		$625K Buy
86,618
+37,252
+75% +$341K 0.01% 580
2024
Q2 		$536K Buy
+49,366
New +$633K 0.01% 565

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Graham Capital Management's SAGE Position: Q3 2025 in Review

Graham Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 154,051 shares — an estimated $1.4M sold.

Graham Capital Management first reported a position in SAGE in Q2 2024 and held it in 5 quarters. The position peaked at $1.4M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Graham Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Graham Capital Management sold 154,051 Sage Therapeutics shares in Q3 2025, an estimated $1.4M.
  • Graham Capital Management first reported a position in Sage Therapeutics in Q2 2024 and held it in 5 quarters.
  • Graham Capital Management's Sage Therapeutics position peaked at $1.4M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.